Dare Bioscience Inc

Research Dare Bioscience Inc (DARE) on Bullrun: market cap USD 12.45M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 12.45M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 1.03M-USD 13.40M-USD 10.27M71.3%-1.2USD 24.71MUSD 2.66MUSD 2.84M
FY2024USD 9.78K-USD 4.05MUSD 4.90M100.0%-0.48USD 15.70MUSD 4.05K-USD 6.01M
FY2023USD 2.81M-USD 30.16M-USD 39.49Mn/a-4.15USD 10.48MUSD 1.40M-USD 5.05M
FY2022USD 10.00M-USD 30.95M-USD 18.15Mn/a-0.37USD 34.67MUSD 582.72KUSD 11.11M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 12.45Mn/an/an/a
20252025-12-31USD 27.98Mn/an/an/a
20242024-12-31USD 27.15Mn/an/an/a
20232023-12-29USD 30.47Mn/an/an/a
20222022-12-30USD 70.38Mn/an/an/a
20212021-12-31USD 167.89Mn/an/an/a

About Dare Bioscience Inc

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Dare Bioscience Inc's market cap?

Dare Bioscience Inc's market capitalization is USD 12.45M.

What does Dare Bioscience Inc do?

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis.